Brokerages Set Envista Holdings Corporation (NYSE:NVST) Price Target at $28.54

Envista Holdings Corporation (NYSE:NVST) has earned a consensus rating of “Hold” from the sixteen analysts that are currently covering the company, MarketBeat.com reports. Ten research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $28.6154.

A number of research firms have commented on NVST. Robert W. Baird lifted their target price on Envista from $30.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Citigroup started coverage on shares of Envista in a research note on Wednesday, April 15th. They set a “neutral” rating and a $29.00 price target on the stock. Morgan Stanley boosted their price target on Envista from $19.00 to $21.00 and gave the company an “equal weight” rating in a report on Friday, April 24th. JPMorgan Chase & Co. upped their price target on Envista from $26.00 to $29.00 and gave the stock a “neutral” rating in a research report on Thursday, May 7th. Finally, BMO Capital Markets started coverage on Envista in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $27.00 price objective on the stock.

Envista Stock Down 2.0%

NVST stock opened at $27.80 on Tuesday. The business has a 50 day moving average of $25.52 and a 200 day moving average of $25.88. The firm has a market cap of $4.52 billion, a PE ratio of 67.81, a price-to-earnings-growth ratio of 1.61 and a beta of 0.86. Envista has a twelve month low of $18.77 and a twelve month high of $30.42. The company has a quick ratio of 2.06, a current ratio of 2.44 and a debt-to-equity ratio of 0.47.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.05. The company had revenue of $705.50 million for the quarter, compared to analysts’ expectations of $680.03 million. Envista had a net margin of 2.41% and a return on equity of 7.11%. Envista’s revenue was up 14.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.24 EPS. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. On average, research analysts forecast that Envista will post 1.42 EPS for the current fiscal year.

Institutional Investors Weigh In On Envista

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NVST. Parallel Advisors LLC increased its position in Envista by 13.1% during the 4th quarter. Parallel Advisors LLC now owns 3,175 shares of the company’s stock valued at $69,000 after buying an additional 367 shares in the last quarter. Bank of Montreal Can boosted its holdings in Envista by 1.4% in the fourth quarter. Bank of Montreal Can now owns 26,178 shares of the company’s stock worth $568,000 after acquiring an additional 372 shares in the last quarter. Sepio Capital LP grew its stake in shares of Envista by 1.2% during the fourth quarter. Sepio Capital LP now owns 31,632 shares of the company’s stock worth $687,000 after acquiring an additional 374 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Envista by 2.9% during the fourth quarter. Deutsche Bank AG now owns 17,412 shares of the company’s stock worth $378,000 after acquiring an additional 484 shares during the last quarter. Finally, State of Michigan Retirement System increased its holdings in shares of Envista by 1.5% during the first quarter. State of Michigan Retirement System now owns 39,463 shares of the company’s stock valued at $1,001,000 after acquiring an additional 600 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.